uniQure (NASDAQ:QURE) Receives Average Rating of “Buy” from Brokerages

Shares of uniQure (NASDAQ:QURE) have been assigned a consensus rating of “Buy” from the ten research firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $33.88.

Several brokerages have recently issued reports on QURE. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. Guggenheim restated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Cantor Fitzgerald upped their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. Leerink Partners increased their target price on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Finally, Mizuho boosted their price target on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th.

Insider Buying and Selling at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QURE. RTW Investments LP acquired a new stake in shares of uniQure during the third quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. increased its holdings in uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares in the last quarter. Atria Investments Inc bought a new position in uniQure in the 3rd quarter valued at $53,000. Quarry LP acquired a new position in uniQure in the third quarter worth $58,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Stock Down 9.8 %

QURE stock opened at $15.92 on Thursday. The stock has a market capitalization of $775.99 million, a price-to-earnings ratio of -3.21 and a beta of 0.41. The company has a 50-day moving average of $10.83 and a two-hundred day moving average of $7.85. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, equities research analysts anticipate that uniQure will post -3.82 EPS for the current year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.